Secci, DanielaCarradori, SimonePetzer, AnelGuglielmi, PaoloD'Ascenzio, MelissaChimenti, PaolaBagetta, DonatellaAlcaro, StefanoZengin, GökhanPetzer, Jacobus P.Ortuso, Francesco2020-03-262020-03-262019Secci, D., Carradori, S., Petzer, A., Guglielmi, P., D’Ascenzio, M., Chimenti, P., Bagetta, D., Alcaro, S., Zengin, G., Petzer, J. P., Ortuso, F. (2019). 4-(3-Nitrophenyl)Thiazol-2-Ylhydrazone Derivatives as Antioxidants and Selective Hmao-B İnhibitors: Synthesis, Biological Activity and Computational Analysis, 34(1), 597-612.1475-63661475-6374https://dx.doi.org/10.1080/14756366.2019.1571272https://hdl.handle.net/20.500.12395/37384A new series of 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives were designed, synthesised, and evaluated to assess their inhibitory effect on the human monoamine oxidase (hMAO) A and B isoforms. Different (un)substituted (hetero)aromatic substituents were linked to N1 of the hydrazone in order to establish robust structure-activity relationships. The results of the biological testing demonstrated that the presence of the hydrazothiazole nucleus bearing at C4 a phenyl ring functionalised at the meta position with a nitro group represents an important pharmacophoric feature to obtain selective and reversible human MAO-B inhibition for the treatment of neurodegenerative disorders. In addition, the most potent and selective MAO-B inhibitors were evaluated in silico as potential cholinesterase (AChE/BuChE) inhibitors and in vitro for antioxidant activities. The results obtained from molecular modelling studies provided insight into the multiple interactions and structural requirements for the reported MAO inhibitory properties.en10.1080/14756366.2019.1571272info:eu-repo/semantics/openAccess(Thiazol-2-yl)hydrazone derivativesAlzheimer's diseaseParkinson's diseaseSelectiveMonoamine oxidaseInhibitorAntioxidantsMolecular modellingArticle34159761230727777Q1WOS:000457961800001Q1